RIGEL PHARMACEUTICALS, INC. (RIGL) Total liabilities 2016–2025
RIGEL PHARMACEUTICALS, INC. (RIGL) total liabilities at each fiscal year-end, per SEC filings.
$122.1MFY2025 · since FY2016: $23.1M → $122.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $122.1M | -24.0% |
| FY2024 | $160.7M | +10.2% |
| FY2023 | $145.9M | -1.4% |
| FY2022 | $147.9M | +8.0% |
| FY2021 | $137.0M | +79.4% |
| FY2020 | $76.4M | -18.6% |
| FY2019 | $93.8M | +220.7% |
| FY2018 | $29.2M | +58.3% |
| FY2017 | $18.5M | -20.1% |
| FY2016 | $23.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RIGL financial trends
RIGL RevenueRIGL Net incomeRIGL Net marginRIGL Gross profitRIGL Gross marginRIGL Operating incomeRIGL Operating marginRIGL Operating cash flowRIGL Free cash flowRIGL Capital expendituresRIGL Return on equityRIGL Stock buybacksRIGL Dividends paidRIGL Total assetsRIGL Shareholders’ equityRIGL overview →